Phase II Study of Cilengitide in Combination With Concurrent Chemotherapy and Radiotherapy Followed by Protracted Daily Low Dose Temozolomide and Low Dose Procarbazine D1 - 20 in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Promoter Gene.

Trial Profile

Phase II Study of Cilengitide in Combination With Concurrent Chemotherapy and Radiotherapy Followed by Protracted Daily Low Dose Temozolomide and Low Dose Procarbazine D1 - 20 in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Promoter Gene.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Cilengitide (Primary) ; Procarbazine; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms ExCentric
  • Most Recent Events

    • 17 Feb 2015 Planned primary completion date changed to 1 Nov 2012.
    • 30 May 2014 Interim results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2011 Trial design has been reported at the Trials in Progress Poster Session at ASCO 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top